- Home
- ONDS vs RPHM Comparison
ONDS vs RPHM Comparison
Compare ONDS & RPHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- RPHM
- Stock Information
- Founded
- ONDS N/A
- RPHM 2014
- Country
- ONDS United States
- RPHM United States
- Employees
- ONDS N/A
- RPHM N/A
- Industry
- ONDS Telecommunications Equipment
- RPHM Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- RPHM Health Care
- Exchange
- ONDS Nasdaq
- RPHM Nasdaq
- Market Cap
- ONDS 52.7M
- RPHM 47.5M
- IPO Year
- ONDS N/A
- RPHM 2021
- Fundamental
- Price
- ONDS $0.75
- RPHM $1.82
- Analyst Decision
- ONDS Strong Buy
- RPHM Hold
- Analyst Count
- ONDS 2
- RPHM 6
- Target Price
- ONDS $2.50
- RPHM $2.26
- AVG Volume (30 Days)
- ONDS 398.0K
- RPHM 345.4K
- Earning Date
- ONDS 11-12-2024
- RPHM 11-11-2024
- Dividend Yield
- ONDS N/A
- RPHM N/A
- EPS Growth
- ONDS N/A
- RPHM N/A
- EPS
- ONDS N/A
- RPHM N/A
- Revenue
- ONDS $9,209,335.00
- RPHM N/A
- Revenue This Year
- ONDS N/A
- RPHM N/A
- Revenue Next Year
- ONDS $217.16
- RPHM N/A
- P/E Ratio
- ONDS N/A
- RPHM N/A
- Revenue Growth
- ONDS 0.36
- RPHM N/A
- 52 Week Low
- ONDS $0.32
- RPHM $0.98
- 52 Week High
- ONDS $1.99
- RPHM $9.21
- Technical
- Relative Strength Index (RSI)
- ONDS 46.98
- RPHM 69.89
- Support Level
- ONDS $0.68
- RPHM $1.61
- Resistance Level
- ONDS $0.83
- RPHM $1.75
- Average True Range (ATR)
- ONDS 0.06
- RPHM 0.13
- MACD
- ONDS 0.00
- RPHM 0.04
- Stochastic Oscillator
- ONDS 49.18
- RPHM 87.30
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About RPHM Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.